Tag: Hatch-Waxman Act
Pharmaceutical Antitrust Complexity
This article is part of a Chronicle. See more from this Chronicle
Michael Carrier, Nov 24, 2014
The pharmaceutical industry is unique in its complexity. Markets...
Generic Drugmakers Will Challenge Patents Even When They Have a 97%...
Jonathan Gleklen, Kelly Smith, Sep 13, 2012
A striking aspect of the Third Circuit's decision on Hatch-Waxman patent settlements in the K-Dur litigation is the panel's...
Cervantes Sequel: The FTC’s Quest to End Pay-for-Delay Pharma Settlements
Anne Layne-Farrar, Jun 27, 2012
We are drawing close to the thirtieth anniversary of the Drug Price Competition and Patent Term Restoration Act, better known...
Reverse Payment Settlements: Presumptively Bad or Usually Acceptable?
Kyle Musgrove, Richard Ripley, Jun 27, 2012
In April 2012, the Federal Trade Commission ("FTC") suffered yet another rebuke of what FTC Chair Jon Leibowitz...
Federal Trade Commission Rejected in “Reverse Payment” Suit
Kevin Noonan, Jun 27, 2012
The Federal Trade Commission in recent years has identified a practice it considers to be a threat to consumers regarding...
